Quintiles selected as Bristol-Myers ‘preferred provider’

Quintiles has locked up more work with drug maker Bristol-Myers Squibb (NYSE:BMY)

The Durham pharmaceutical services company has been chosen as a “preferred provider” offering global support for Bristol-Myers’ central lab work, biomarker testing and assay development over the next five years.

Pharmaceutical companies and contract research organizations such as Quintiles have increasingly been striking these partnership deals, which pledge to a CRO more work over a longer period of time. Quintiles, which has filed for a $600 million initial public offering, is the largest CRO in the pharmaceutical services industry. No financial terms of the relationship with Bristol-Myers were disclosed.